Medical Oncology

, Volume 17, Issue 3, pp 229–232

A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?

Case Report

DOI: 10.1007/BF02780534

Cite this article as:
Enblad, G., Carlson, K., Bengtsson, M. et al. Med Oncol (2000) 17: 229. doi:10.1007/BF02780534


Patients with Hodgkin's disease (HD) or large cell lymphomas who relapse after conventional chemotherapy have a poor prognosis without high-dose chemotherapy and stem cell transplantation (HDCT). Patients who relapse after HDCT have an extremely poor outcome. In the present study we describe four patients with relapsed HD (n=1) and large cell lymphomas (n=3) after HDCT. All had an aggressive clinical course before HDT. At relapse, however, they all have had prolonged remissions and/or spontaneous regressions on mild or no treatment. Possible explanations could be selection of less malignant clones or a lymphoma controlled by the immune system. The mechanisms are, however, unknown but warrant further studies of the molecular biology in these and similar cases.


ABMTrelapsehigh-dose chemotherapy

Copyright information

© Macmillan Publishers Ltd 2000

Authors and Affiliations

  1. 1.Departments of Oncology, Radiology and Clinical ImmunologyUppsala University, Akademiska sjukhusetUppsalaSweden
  2. 2.Department of HaematologyUppsala University, Akademiska sjukhusetUppsalaSweden